Bristol-Myers Squibb vs Burlington: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Burlington was founded in 1972 by Monroe Milstein and is led by Michael O'Sullivan.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Burlington
- Founded
- 1972
- Headquarters
- Burlington, New Jersey
- Current CEO
- Michael O'Sullivan
- Employees
- 83,309
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Burlington
Monroe Milstein
Monroe G. Milstein grew up in his family's wholesale outerwear business in New York.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Burlington
- Monroe Milstein1972–2006
Founder and Chief Executive Officer
Milstein opened the first Burlington Coat Factory in Burlington, New Jersey, in 1972, broadened it from discount coats into year-round family apparel, shoes, baby and home goods, and took it public in 1983.
Source - Mark Nesci2006–2008
Chief Executive Officer
A 37-year Burlington veteran, Nesci became CEO in 2006 after Bain Capital took the company private for about $2.06 billion. He retired in December 2008, remaining an equity investor and senior adviser to the board.
Source - Tom Kingsbury2008–2019
President and Chief Executive Officer
A former Kohl's senior executive, Kingsbury was hired by Bain Capital in December 2008 to revamp buying, inventory management and the supply chain.
Source - Michael O'Sullivan2019–present
Chief Executive Officer
O'Sullivan joined from Ross Stores, where he spent 16 years and finished as president and COO, and became CEO around September 16, 2019.
Source
Timeline: Bristol-Myers Squibb and Burlington side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1972Burlington
Burlington Coat Factory opens
Monroe Milstein bought a coat outlet in a former factory building in Burlington, New Jersey, and sold brand-name coats at discount prices, the start of Burlington Coat Factory.
1983Burlington
First public offering
Burlington Coat Factory Warehouse Corporation went public for the first time, funding expansion from a regional discounter into a national chain with year-round apparel, shoes, baby and home departments.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1989Burlington
Cohoes Specialty Stores acquired
Burlington bought the Cohoes Specialty Stores off-price chain from upstate New York, including a 50 percent stake in the Cohoes Commons building; a few stores still traded as Cohoes Fashions decades later.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2006Burlington
Bain Capital takes Burlington private
Bain Capital acquired Burlington Coat Factory for about $2.06 billion, ending 34 years of Milstein family control. Long-time executive Mark Nesci became chief executive.
2008Burlington
Tom Kingsbury named CEO
Former Kohl's executive Thomas Kingsbury became president and CEO in December 2008, succeeding Mark Nesci, and began overhauling buying, inventory management and the supply chain.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2013Burlington
Return to the stock market
Burlington Stores priced its IPO on October 2, 2013, selling 13.3 million shares at $17 each for about $226 million, and listed under the ticker BURL.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2019Burlington
Michael O'Sullivan becomes CEO
Former Ross Stores president and COO Michael O'Sullivan succeeded Tom Kingsbury as CEO around September 16, 2019, and later launched the Burlington 2.0 plan of leaner inventories and smaller stores.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2020Burlington
Online sales end and stores close for the pandemic
On March 5, 2020, Burlington said it would shut its e-commerce business. Days later pandemic lockdowns closed its stores, and fiscal 2020 revenue fell to $5.76 billion with a $216.5 million net loss.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023Burlington
Bed Bath & Beyond leases
Burlington won 44 Bed Bath & Beyond leases for $12 million at the June 2023 bankruptcy auction, the largest share of the 109 sold, and later reported 62 former Bed Bath & Beyond leases in total.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Burlington
Joann leases
After Joann's second bankruptcy, Burlington agreed in April 2025 to take over 45 Joann store leases, many of which became part of its fiscal 2026 opening program.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Burlington
Record fiscal 2025 results
Burlington reported fiscal 2025 total revenue of $11.57 billion and net income of $610.2 million, and ended the year on January 31, 2026, with 1,212 stores.
2026Burlington
Tariff refunds put into prices
In the second quarter of fiscal 2026, sales rose 11 percent to $2.998 billion. Burlington received $55 million in tariff refunds and said it would reinvest them in lower prices; the store count reached 1,287.
2026Burlington
Headquarters move to Philadelphia announced
On September 3, 2026, Burlington said it will invest $370 million to move its headquarters from Burlington Township, New Jersey, to Schuylkill Yards in Philadelphia, in phases from late 2028 or early 2029.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Burlington
- Joann store leases2025Undisclosed
- Bed Bath & Beyond store leases2023$12M
- Burlington Coat Factory (taken private by Bain Capital)2006$2.1B
- Cohoes Specialty Stores (Cohoes Fashions)1989Undisclosed
Questions about Bristol-Myers Squibb vs Burlington
Who is the CEO of Bristol-Myers Squibb Company and Burlington Stores, Inc.?
Bristol-Myers Squibb Company is led by Christopher Boerner and Burlington Stores, Inc. is led by Michael O'Sullivan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Burlington Stores, Inc.?
Bristol-Myers Squibb Company was founded in 1887 — 85 years before Burlington Stores, Inc., which was founded in 1972. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Burlington Stores, Inc..
How many employees does Bristol-Myers Squibb Company have compared to Burlington Stores, Inc.?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Burlington Stores, Inc. employs approximately 83,309. Burlington Stores, Inc. has the larger workforce at 83,309 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Burlington Stores, Inc. headquartered?
Both Bristol-Myers Squibb Company and Burlington Stores, Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bristol-Myers Squibb Company and Burlington Stores, Inc.?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Burlington Stores, Inc. was founded by Monroe Milstein.
Which company has a longer operating history — Bristol-Myers Squibb Company or Burlington Stores, Inc.?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Burlington Stores, Inc. has been in operation for around 54 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Burlington overview